Method of treating ciliated tissue using CSA micelles
US12070467B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Mar 7, 2019 |
| Grant date | Aug 27, 2024 |
| Priority date | — |
| Expiry date | Jul 5, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P31/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure describes treatment compositions and methods for preventing and/or treating microbial infections of ciliated tissues, such as tissues of the trachea, lungs, and sinuses. The method utilizes a treatment composition that includes a cationic steroidal antimicrobial (CSA) compound, a poloxamer, and a carrier, which is administered to ciliated tissue, such as lung tissue, in order to prevent or treat a microbial infection by killing microbes associated with the ciliated tissue. The poloxamer forms micelles that encapsulate the CSA compound, the poloxamer being included in the treatment composition in an amount, by weight, that is about 100 to 1000 times the amount of the CSA compound.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.